Literature DB >> 21937588

Thymidine kinase 2 mutations in autosomal recessive progressive external ophthalmoplegia with multiple mitochondrial DNA deletions.

Henna Tyynismaa1, Ren Sun, Sofia Ahola-Erkkilä, Henrikki Almusa, Rosanna Pöyhönen, Mari Korpela, Jari Honkaniemi, Pirjo Isohanni, Anders Paetau, Liya Wang, Anu Suomalainen.   

Abstract

Autosomal-inherited progressive external ophthalmoplegia (PEO) is an adult-onset disease characterized by the accumulation of multiple mitochondrial DNA (mtDNA) deletions in post-mitotic tissues. Mutations in six different genes have been described to cause the autosomal dominant form of the disease, but only mutations in the DNA polymerase gamma gene are known to cause autosomal recessive PEO (arPEO), leaving the genetic background of arPEO mostly unknown. Here we used whole-exome sequencing and identified compound heterozygous mutations, leading to two amino acid alterations R225W and a novel T230A in thymidine kinase 2 (TK2) in arPEO patients. TK2 is an enzyme of the mitochondrial nucleotide salvage pathway and its loss-of-function mutations have previously been shown to underlie the early-infantile myopathic form of mtDNA depletion syndrome (MDS). Our TK2 activity measurements of patient fibroblasts and mutant recombinant proteins show that the combination of the identified arPEO variants, R225W and T230A, leads to a significant reduction in TK2 activity, consistent with the late-onset phenotype, whereas homozygosity for R225W, previously associated with MDS, leads to near-total loss of activity. Our finding identifies a new genetic cause of arPEO with multiple mtDNA deletions. Furthermore, MDS and multiple mtDNA deletion disorders are manifestations of the same pathogenic pathways affecting mtDNA replication and repair, indicating that MDS-associated genes should be studied when searching for genetic background of PEO disorders.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21937588     DOI: 10.1093/hmg/ddr438

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  35 in total

1.  Oxidative stress induced S-glutathionylation and proteolytic degradation of mitochondrial thymidine kinase 2.

Authors:  Ren Sun; Staffan Eriksson; Liya Wang
Journal:  J Biol Chem       Date:  2012-06-01       Impact factor: 5.157

2.  Deoxycytidine and Deoxythymidine Treatment for Thymidine Kinase 2 Deficiency.

Authors:  Carlos Lopez-Gomez; Rebecca J Levy; Maria J Sanchez-Quintero; Martí Juanola-Falgarona; Emanuele Barca; Beatriz Garcia-Diaz; Saba Tadesse; Caterina Garone; Michio Hirano
Journal:  Ann Neurol       Date:  2017-05-04       Impact factor: 10.422

Review 3.  Mitochondria: in sickness and in health.

Authors:  Jodi Nunnari; Anu Suomalainen
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

Review 4.  Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options.

Authors:  Ayman W El-Hattab; Fernando Scaglia
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

Review 5.  Mitochondrial Diseases Part II: Mouse models of OXPHOS deficiencies caused by defects in regulatory factors and other components required for mitochondrial function.

Authors:  Luisa Iommarini; Susana Peralta; Alessandra Torraco; Francisca Diaz
Journal:  Mitochondrion       Date:  2015-01-29       Impact factor: 4.160

6.  MPV17 Mutations Causing Adult-Onset Multisystemic Disorder With Multiple Mitochondrial DNA Deletions.

Authors:  Caterina Garone; Juan Carlos Rubio; Sarah E Calvo; Ali Naini; Kurenai Tanji; Salvatore Dimauro; Vamsi K Mootha; Michio Hirano
Journal:  Arch Neurol       Date:  2012-12

7.  Inborn errors of pyrimidine metabolism: clinical update and therapy.

Authors:  Shanti Balasubramaniam; John A Duley; John Christodoulou
Journal:  J Inherit Metab Dis       Date:  2014-07-17       Impact factor: 4.982

8.  TK2 mutation presenting as indolent myopathy.

Authors:  Carmen Paradas; Purificacion Gutiérrez Ríos; Eloy Rivas; Pilar Carbonell; Michio Hirano; Salvatore DiMauro
Journal:  Neurology       Date:  2013-01-09       Impact factor: 9.910

Review 9.  Next-generation sequencing for mitochondrial disorders.

Authors:  C J Carroll; V Brilhante; A Suomalainen
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

10.  In vitro supplementation with deoxynucleoside monophosphates rescues mitochondrial DNA depletion.

Authors:  Stefanie Bulst; Elke Holinski-Feder; Brendan Payne; Angela Abicht; Sabine Krause; Hanns Lochmüller; Patrick F Chinnery; Maggie C Walter; Rita Horvath
Journal:  Mol Genet Metab       Date:  2012-05-03       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.